Halozyme Therapeutics Inc (HALO)
A research Signal Score of unusual activity and the signals behind it. Not advice, not a prediction, not yet backtested.
Our last 30 days of resolved calls came true 29% of the time.See the track record →
Figures reflect the most recent reported period. Margins, ROE and growth are percentages; Debt/Equity and Current ratio are ratios.
A generic 2:1 reward-to-risk example (about a 10% stop and 20% target). Illustrative and educational, not advice. Set your own levels for your risk tolerance.
- Session momentumUp 2.1% on the session+5
- 12-month trend+39% over the past year+3
- 52-week positionPressing 52-week highs+30
- QualityRevenue growing 41% y/y+10
- VolumeNo intraday volume on the free data tier — this factor is disabled, not faked.+0
Score uses live volume/momentum/breakout signals today; insider buying, short interest, options flow and social velocity layer in as those sources come online. How it works →
🤖 The dominant catalyst here is **analyst/sentiment-driven** rather than a hard fundamental event, since the headlines center on conference presentations and value-screen inclusions rather than earnings, product data, or M&A. Continuation likelihood over the next few weeks is **moderate-to-low (roughly 30–40%)**, as screen-based and conference-driven attention tends to fade without a fresh operational catalyst. Informational only — not financial advice.
- 3 Reasons Why Growth Investors Shouldn't Overlook Halozyme Therapeutics (HALO)Yahoo · 2026-09-16
- Halozyme Therapeutics, Inc. (HALO) Presents at H.C. Wainwright 28th Annual Global Investment Conference TranscriptSeekingAlpha · 2026-09-16
- Zacks.com featured highlights include Halozyme Therapeutics, Avnet, BILL and Venture GlobalYahoo · 2026-09-15
- 4 Value Stocks to Buy as Oil Surge Fuels Fed Rate Hike FearsYahoo · 2026-09-15
- Halozyme Therapeutics, Inc. (HALO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha · 2026-09-15
Any AI summary is an interpretation of public news, not advice or a price target.